Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital

Size: px
Start display at page:

Download "Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital"

Transcription

1 Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital

2 Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier Research Grants: European Union Associate Editor: European Heart Journal, Int J Cardiol Journal of CV Medicine

3 EVERYTHING

4 Outcome in acute HF is still poor DOSE CARRESS-HF Death, Rehospitalization or ER visit 40% at 60 days

5 Chronic HF survival rates have improved over time with the advent of new therapies Temporal trends in 5-year mortality after the diagnosis of HF by gender show improvements in survival Survival (%) Men Survival (%) Women Years Years... nevertheless, the 5-year mortality rate remains high Population-based cohort study analysing data from the Rochester Epidemiology Project, Minnesota, USA. 4,537 patients with a diagnosis of HF between 1979 and 2000 were included. Framingham criteria and clinical criteria were used to validate the diagnosis. Roger et al. JAMA 2004;292:344 50

6 WE NEED Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

7 Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

8

9 Diagnostic algorithm for a diagnosis of heart failure of non-acute onset

10 Diagnostic algorithm for a diagnosis of heart failure of non-acute onset

11 Causes of elevation of natriuretic peptides levels Interpretation of Natriuretic Peptides

12 Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

13 13 New Classification and Diagnosis New Classification! Heart failure with preserved, mid-range and reduced EF it is only in patients with HFrEF that therapies have been shown to reduce both morbidity and mortality

14 14 Signs (± symptoms) of HF Structural abnormalities LAVI >34ml/m 2 + HFpEF: EF 50% HFmrEF: EF 40-49% + Functional abnormalitie s E/e avg 13 Diagnosis of HFpEF/ HFmrEF Limited data (Unmet Need!) Cut-offs arbitrary More criteria; greater certainty of diagnosis Diastolic stress test? Invasive hemodynamic measurements? LVMI >115g/m 2 (m) >95 g/m 2 ( f ) e average (lateralseptal) < 9 cm/s

15 Heart Failure: TNM-Like Classification HLM ClassificationIn each column, different stages of heart (H-1 to H-4), lung (L-0 to L-3), and peripheral organ involvement (i.e., kidney, liver, and brain [M-0 to M-3] Francesco Fedele, Paolo Severino, Simone Calcagno, Massimo Mancone Journal of the American College of Cardiology, Volume 63, Issue 19, 2014,

16 from Filippatos et al Heart Fail Rev 2007 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

17 Classification of AHFS ACS with Heart Failure PULMONARY EDEMA Hypertensive AHF or Vascular AHF or De Novo AHF Right Heart Failure Normotensive AHF or Cardiac Failure or Acutely Decompensated Chronic HF Hypotensive AHF/ Cardiogenic shock Filippatos G et al. Heart Failure Rev 2007

18

19 Management of patients with acute heart failure based on clinical profile during an early phase

20 Gheorghiade and Braunwald. JAMA 2011;305:

21 Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

22 EVEREST Trials: Continental Differences 4133 patients admitted with AHF and reduced LVEF on standard medical therapy followed 9.9 months North America South America Western Europe Eastern Europe P-value 1-year Estimate, %, (95% CI) Death 30.4 ( ) 27.2 ( ) 27.1 ( ) 20.5 ( ) < CV death/hf hospitalization 52.5 ( ) 41.6 ( ) 47.3 ( ) 35.3 ( ) <0.0001

23 Variation in death and re-admission =30 days =1 year 40 Death 60 HF re-admission Proportion (%) Scotland Glasgow Alberta Turin Denmark 0 land gow erta urin ark

24 REPORT-HF Registry: Global Outreach # Modified from Filippatos et al. Eur J Heart Fail. 2015;17(5):527-33;

25 Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

26 AHF: Pathophysiology Myocardial injury Apoptosis Extracellular matrix Acute BP Arrhythmias Ischemia Age, LVH Renal dysfunction Impaired relaxation, Stiffness Neurohormonal activation Increased Afterload Filling pressures Stroke volume Filippatos G et al. Am J Physiol 1999;277:H445, Jain P et al. Am Heart J. 2003;

27 Potential pathogenetic pathways linking heart failure with renal dysfunction. Filippatos G et al. Eur Heart J 2014

28

29 From: Braunwald s Heart Disease. 9th ed. Philadelphia,

30 AHF (and WRF) in patients with or wo CKD

31 What to do next? 1. Increase furosemide dose 2. Ιntravenous infusion rather than bolus therapy 3. Substitution of an ineffective loop diuretic for another one 4. Add metolazone and/ or potasium sparing diuretic 5. Add dopamine at 2-5 mcg/k/m 6. Withdraw b-blocker and/ or ACE inhibitor 7. Add dobutamine 8. Add levosimendan 9. Start ultrafiltration 10. Start dialysis 11. Insert IABP 12. Insert another device Maisel A, Filippatos G. In: Heart Failure. Publisher Jaypoor, 2014

32 EURObservational Research Programme Acute HF: persisting congestion at discharge and all-cause mortality during the follow-up 81,6% 24,1% Pulmonary and/or Peripheral congestion At admission 11,3% p<.0001 No 20,8% At discharge Yes

33

34 Early drop in systolic blood pressure and worsening renal function in AHF: renal results of Pre-RELAX-AHF European Journal of Heart Failure vol 13, pages , 2014 DOI: /eurjhf/hfr060

35 Impact of Venous Congestion on Glomerular Net Filtration Pressure Jessup, M. et al. J Am Coll Cardiol 2009;53:

36 Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

37 Treatment Algorithm Available online on Eur J Heart Fail We are HFA

38

39 Better Diagnosis Better Classification Study the Epidemiology around the world Understand better the pathophysiology Therapies that improve mortality and morbidity Is treatment of Acute HFPEF different from Acute HFREF?

40 OPTIMIZE-HF: distribution of patients LVEF Fonarow et al. J Am Coll Cardiol. 2007; 50(8):768

41 AHF with preserved vs reduced EF: effect of new therapies The two larger RCT trials of ultrafiltration in AHF (UNLOAD and CARRESS-HF) included AHF patients with HFpEF but did not find any significant differences in response to ultrafiltration in HFpEF versus HFrEF. Bart et al. N Engl J Med. 2012; 367(24): In ASCEND trial, nesiritide marginally improved symptom relief without effect on renal function or clinical outcomes, and there was no differential response according to EF (< or 40 %). O'Connor CM et al. N Engl J Med. 2011; 365(1):32 43 In RELAX-AHF, 45 % of patients had EF >40 %, while serelaxin improved dyspnea scores both in patients with HFpEF and HFrEF. Filippatos et al Eur Heart J 2013

42 Forget Anything?

43 0 % Public don t know how to recognise HF Proportion of general public recognising symptoms of heart failure (combination of breathlessness, tiredness and swollen ankles) NL France Spain Ital Romania UK Sweden Poland Germany

44 Public do recognise other cardiovascular conditions General public recognition of description of typical symptoms/signs of three common cardiovascular problems % heart 1 attack stroke 2 heart failure 3

45 MEMBERS: 56 National Cardiac Societies AFFILIATED MEMBERS: 26 National Cardiac Societies

46 29 April 2 May 2017 PARIS, France 4 days of scientific exchange healthcare professionals abstracts and cases submitted 110+ scientific sessions 300+ expert faculty members 100+ countries represented 45+ industry sessions/workshops Call for abstracts: November 3 January 13

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA

Heart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to

More information

ROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association

ROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association ROSE-AHF and Beyond Gerasimos Filippatos, FESC, FHFA President Heart Failure Association From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011 Determinants and forms of worsening renal

More information

Gerasimos Filippatos MD, FESC, FCCP, FACC

Gerasimos Filippatos MD, FESC, FCCP, FACC Gerasimos Filippatos MD, FESC, FCCP, FACC Head of HF Unit at Athens University Hospital, Greece President (2014-2016) of the HF Association of the European Society of Cardiology (ESC) Served as Chair of

More information

Overcoming the Cardiorenal Syndrome

Overcoming the Cardiorenal Syndrome Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland

More information

Pivotal Role of Renal Function in Acute Heart failure

Pivotal Role of Renal Function in Acute Heart failure Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS

More information

Management of Acute Heart Failure

Management of Acute Heart Failure Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.

More information

2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland

2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland 2016 ESC Heart Failure Guidelines: what is new? Piotr Ponikowski Wroclaw, Poland Disclosures Consultancy fees and speaker s honoraria from: Amgen, Servier, Novartis, Johnson & Johnson, Merck, Berlin Chemie,

More information

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014

ACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College

More information

Medical Management of Acute Heart Failure

Medical Management of Acute Heart Failure Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training

More information

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University

More information

Pearls in Acute Heart Failure Management

Pearls in Acute Heart Failure Management Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:

More information

Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;

Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients

More information

Slide 1. Slide 2. Slide 3. Managing Acute Heart Failure Trials and Tribulations. Declaration of

Slide 1. Slide 2. Slide 3. Managing Acute Heart Failure Trials and Tribulations. Declaration of Slide 1 Managing Acute Heart Failure Trials and Tribulations Martin R Cowie MD MSc FRCP FRCP (Ed) FESC Professor of Cardiology, Imperial College London m.cowie@imperial.ac.uk @ProfMartinCowie Slide 2 Declaration

More information

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?

Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor

More information

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling

More information

Acute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra

Acute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.

More information

State of the Art: acute heart failure Is it just congestion?

State of the Art: acute heart failure Is it just congestion? ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456

More information

Cardio-Renal Syndrome in Acute Heart Failure:

Cardio-Renal Syndrome in Acute Heart Failure: Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine

More information

Stopping the Revolving Door of ADHF

Stopping the Revolving Door of ADHF Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center

More information

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Medical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate

More information

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU

Management of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)

More information

The Cardiorenal Syndrome in Heart Failure

The Cardiorenal Syndrome in Heart Failure The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic

More information

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE Mefri Yanni, MD Bagian Kardiologi dan Kedokteran Vaskular RS.DR.M.Djamil Padang The 3rd Symcard Padang, Mei 2013 Outline Diagnosis Diagnosis Treatment options

More information

Practical Points in Cardiorenal Syndrome

Practical Points in Cardiorenal Syndrome Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok

More information

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand

Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical

More information

The Art and Science of Diuretic therapy

The Art and Science of Diuretic therapy The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload

More information

HFpEF: How to optimise management

HFpEF: How to optimise management HFpEF: How to optimise management Burkert Pieske M.D. Berlin, Germany Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, and Department of Internal

More information

Intravenous Inotropic Support an Overview

Intravenous Inotropic Support an Overview Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)

More information

SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016

SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016 Matthias Nägele, MD University Hospital Zurich Disclosures I have nothing to disclose. The new

More information

Recognizing and Treating Patients with the Cardio-Renal Syndrome

Recognizing and Treating Patients with the Cardio-Renal Syndrome Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts

More information

Heart Failure and Renal Disease Cardiorenal Syndrome

Heart Failure and Renal Disease Cardiorenal Syndrome Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National

More information

Systolic and Diastolic Dysfunction: Four Upcoming Challenges

Systolic and Diastolic Dysfunction: Four Upcoming Challenges Systolic and Diastolic Dysfunction: Four Upcoming Challenges Promoting Early Detection HFrEF: Beyond Neprilysin/Enalapril HFmrEF: What Is It and How Does One Manage It? HFpEF: Etiopathogenetic Role and

More information

MANAGEMENT OF ACUTE PULMONARY EDEMA. Pr. NOUIRA Semir Emergency Department Fattouma Bourguiba University Hospital

MANAGEMENT OF ACUTE PULMONARY EDEMA. Pr. NOUIRA Semir Emergency Department Fattouma Bourguiba University Hospital MANAGEMENT OF ACUTE PULMONARY EDEMA Pr. NOUIRA Semir Emergency Department Fattouma Bourguiba University Hospital ACUTE HEART FAILURE 35% 10% Goals of Acute Management Rapidly improve symptoms while preserving

More information

Acute HF is a complex and often life-threatening clinical condition. 1 Existing

Acute HF is a complex and often life-threatening clinical condition. 1 Existing ACUTE HEART FAILURE: WHAT IS NEW? John Parissis, MD, PhD; Vasiliki Bistola, MD Author affiliations: Heart Failure Unit, University of Athens, Athens, Greece Address for correspondence: John Parissis, Navarinou

More information

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished

More information

How to define the target population?

How to define the target population? Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF

More information

Accepted Manuscript. Tolvaptan in Acute Heart Failure: Time to Move On. Randall C. Starling, MD MPH, James B. Young, MD

Accepted Manuscript. Tolvaptan in Acute Heart Failure: Time to Move On. Randall C. Starling, MD MPH, James B. Young, MD Accepted Manuscript Tolvaptan in Acute Heart Failure: Time to Move On Randall C. Starling, MD MPH, James B. Young, MD PII: S0735-1097(16)35324-4 DOI: 10.1016/j.jacc.2016.09.005 Reference: JAC 22962 To

More information

Heart Failure Guidelines For your Daily Practice

Heart Failure Guidelines For your Daily Practice Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine

More information

Ultrafiltration in Decompensated Heart Failure. Description

Ultrafiltration in Decompensated Heart Failure. Description Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 7 Last Review Status/Date: September 2016 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being

More information

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance

Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received

More information

Management of Stage B Heart Failure

Management of Stage B Heart Failure KSC 2017 Management of Stage B Heart Failure Byung Su Yoo, MD., PhD. Division of Cardiology, Wonju College of Medicine, Yonsei University, South Korea Focused on Symptom ASLVSD, ASLVDD LVH HF progression

More information

HFpEF. April 26, 2018

HFpEF. April 26, 2018 HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes

More information

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response

More information

HFpEF, Mito or Realidad?

HFpEF, Mito or Realidad? HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY

More information

HFPEF Echo with Strain vs. MRI T1 Mapping

HFPEF Echo with Strain vs. MRI T1 Mapping HFPEF Echo with Strain vs. MRI T1 Mapping Erik Schelbert, MD MS Director, Cardiovascular Magnetic Resonance Assistant Professor of Medicine Heart & Vascular Institute University of Pittsburgh Disclosures

More information

Advanced Care for Decompensated Heart Failure

Advanced Care for Decompensated Heart Failure Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation

More information

COPD as a comorbidity of heart failure in elderly patients

COPD as a comorbidity of heart failure in elderly patients COPD as a comorbidity of heart failure in elderly patients Professor Mitja Lainscak, MD, PhD, FESC, FHFA Departments of Cardiology and Research&Education, General Hospital Celje Faculty of Medicine, University

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,

More information

Βασιλική Κατσή. Καρδιολόγος ΓNA Ιπποκράτειο

Βασιλική Κατσή. Καρδιολόγος ΓNA Ιπποκράτειο Βασιλική Κατσή Καρδιολόγος ΓNA Ιπποκράτειο 40 διαφάνειες ίσως Και πρέπει και δικαιούνται ΣΥΧΝΟΤΕΡΑ 76-96% 3343 men and 4199 women followed for 25 years, no HF at baseline BP (mm Hg)

More information

HFpEF 2016 : Comorbidities and Outcomes

HFpEF 2016 : Comorbidities and Outcomes HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart

More information

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2 HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old

More information

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.

State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr

More information

Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες

Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες Στράτος Θεοφιλογιαννάκος, MD, PhD Ιατρείο Καρδιακής Ανεπάρκειας, Γ Πανεπιστημιακή Καρδιολογική Κλινική ΑΠΘ, ΠΓΝ Ιπποκράτειο

More information

Cardiorenal Syndrome

Cardiorenal Syndrome Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural

More information

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder

More information

Cardiorenal Syndrome

Cardiorenal Syndrome SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal

More information

Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.

Case Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute. Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center

More information

Aldosterone Antagonist. Hyd/ISDN*

Aldosterone Antagonist. Hyd/ISDN* Μedical management of heart failure: Update 2014 Dr John T Parissis Attikon University Hospital Athens, Greece Disclosures: Received honoraria as consultant or research grants by Orion- Pharma, Servier,

More information

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.

THE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D. THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios

More information

Acute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm

Acute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen

More information

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney

Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the

More information

UPDATES IN MANAGEMENT OF HF

UPDATES IN MANAGEMENT OF HF UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion

More information

Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials

Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology

More information

Hyponatremia as a Cardiovascular Biomarker

Hyponatremia as a Cardiovascular Biomarker Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the

More information

The right heart: the Cinderella of heart failure

The right heart: the Cinderella of heart failure The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine

Cardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular

More information

Management of chronic heart failure: update J. Parissis Attikon University Hospital

Management of chronic heart failure: update J. Parissis Attikon University Hospital Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure

More information

WHAT S NEW IN HEART FAILURE

WHAT S NEW IN HEART FAILURE WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School

More information

Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure

Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated

More information

Monitoring of Renal Function in Heart Failure

Monitoring of Renal Function in Heart Failure Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,

More information

2016 Update to Heart Failure Clinical Practice Guidelines

2016 Update to Heart Failure Clinical Practice Guidelines 2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes

More information

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA

Heart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment

More information

What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)

What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr) What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE Marc Ferrini (Lyon Fr) Palermo (I) 1 04 2017 Consulting Fees, Honoraria: BAYER PHARMA BOEHRINGER INGELHEIM BRISTOL MEYERS

More information

The role of remote monitoring in preventing readmissions after acute heart failure

The role of remote monitoring in preventing readmissions after acute heart failure The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure

More information

Diastolic Heart Failure (HFpEF) Felix J. Rogers, DO, FACOI April 29, 2018

Diastolic Heart Failure (HFpEF) Felix J. Rogers, DO, FACOI April 29, 2018 Diastolic Heart Failure (HFpEF) Felix J. Rogers, DO, FACOI April 29, 2018 Case presentation MSO, an 81 year old woman was admitted to HFWH because of progressive dyspnea and difficult to control hypertension

More information

The new Guidelines: Focus on Chronic Heart Failure

The new Guidelines: Focus on Chronic Heart Failure The new Guidelines: Focus on Chronic Heart Failure Petros Nihoyannopoulos MD, FRCP, FESC Professor of Cardiology Imperial College London and National & Kapodistrian University of Athens 2 3 4 The principal

More information

State of the Art Treatment - Hyponatremia, Heart Rate, et al

State of the Art Treatment - Hyponatremia, Heart Rate, et al State of the Art Treatment - Hyponatremia, Heart Rate, et al Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from

More information

Raising expectations for Acute Heart Failure: What does the future bring to us?

Raising expectations for Acute Heart Failure: What does the future bring to us? Raising expectations for Acute Heart Failure: What does the future bring to us? Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland Speaker

More information

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics

More information

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication

More information

Mihai Gheorghiade MD

Mihai Gheorghiade MD Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos

More information

Clinical Policy: Ultrafiltration for Heart Failure Reference Number: CP.MP.456

Clinical Policy: Ultrafiltration for Heart Failure Reference Number: CP.MP.456 Clinical Policy: Reference Number: CP.MP.456 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Heart Failure: Guideline-Directed Management and Therapy

Heart Failure: Guideline-Directed Management and Therapy Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the

More information

THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION

THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine Disclosures Data

More information

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Heart Failure with Preserved EF (HFPEF) Epidemiology and management Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se

More information

Hyponatremia in Heart Failure: why it is important and what should we do about it?

Hyponatremia in Heart Failure: why it is important and what should we do about it? Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and

More information

The ACC Heart Failure Guidelines

The ACC Heart Failure Guidelines The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA

More information

Acute Heart Failure 2017

Acute Heart Failure 2017 Acute Heart Failure 2017 Acute Heart Failure 2017 Heart Failure Definitions HFrEF, HFmrEF. EFpEF Acute Decompensated Heart Failure De Novo presentation Decompensation of Chronic Heart Failure Longer Term

More information

Disclosure Information : No conflict of interest

Disclosure Information : No conflict of interest Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.

More information

New CHF Patient in my Office: What Should I Do?

New CHF Patient in my Office: What Should I Do? New CHF Patient in my Office: What Should I Do? Joseph Mishkin MD FACC Advanced Heart Failure, Transplantation and Mechanical Circulatory Support No disclosures Disclosures Clinical Presentation 38 year

More information

Heart failure hospitalizations with preserved or reduced ejection fraction

Heart failure hospitalizations with preserved or reduced ejection fraction Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,

More information

Diastolic Heart Failure Uri Elkayam, MD

Diastolic Heart Failure Uri Elkayam, MD Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A

More information

Ultrafiltration in Decompensated Heart Failure. Description

Ultrafiltration in Decompensated Heart Failure. Description Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 9 Last Review Status/Date: September 2014 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being

More information

Uri Elkayam, MD. Professor of Medicine University of Southern California Keck School of Medicine

Uri Elkayam, MD. Professor of Medicine University of Southern California Keck School of Medicine Mihai Gheorghiade, MD Memorial Lecture Use of Vasopressin Antagonists for the Management of Hyponatremia and Volume Overload Uri Elkayam, MD Professor of Medicine University of Southern California Keck

More information

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from

More information

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest

More information